Search Clinical Trials in the European Union

Duration
Visits
Confirmation phase (III)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
41-60 of 1,307 trials

Early Breast Cancer: Imlunestrant vs Standard Therapy

We are studying a new treatment called imlunestrant for patients with early breast cancer who have already received 2 to 5 years of standard therapy. The goal is to see if it helps reduce the risk of cancer returning compared to current treatments.

Breast Cancer>2 yearsConfirmation phase (III)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Early Breast Cancer: Camizestrant vs. Standard Therapy

We are studying whether the new medication camizestrant can better prevent breast cancer recurrence in patients who have completed initial treatment. This trial involves individuals with ER+/HER2- early breast cancer at risk of returning after standard therapy.

ER+/HER2- Early Breast Cancer>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Multiple Sclerosis: Rituximab vs. Ocrelizumab Study

We are comparing two treatments for relapsing-remitting multiple sclerosis to see if rituximab is as effective as ocrelizumab in preventing disease activity. This study also examines patient quality of life and other important factors.

Multiple Sclerosis1-2 yearsConfirmation phase (III)Monitoring phase (IV)6-10 visitsStandard MedicinesNeurology

Acute Lymphoblastic Leukaemia: ALLTogether Treatment Study

We are studying new treatment options for children and young adults aged 0-45 with newly diagnosed acute lymphoblastic leukaemia. The goal is to improve survival and quality of life through various interventions.

Acute Lymphoblastic Leukaemia>2 yearsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesHematologyOncology

ANCA-Associated Vasculitis: Pioglitazone Treatment

We are studying whether adding pioglitazone to standard treatments can improve kidney function in patients with ANCA-associated vasculitis. The trial also looks at quality of life and potential side effects.

ANCA-associated Vasculitis>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesPartially RemoteNephrologyRheumatology

Biliary Atresia: Long-term Study of Odevixibat

We are studying the long-term effects of odevixibat in children with biliary atresia to see if it helps improve liver health and overall growth. The trial also looks at the safety of this treatment over time.

Biliary Atresia>2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHepatologyPediatrics

Infantile-onset Pompe Disease: Cipaglucosidase Alfa/Miglustat Study

We are evaluating a new treatment for children under 18 with infantile-onset Pompe disease to see if it is safe and effective. This study includes both children who have and have not received previous enzyme replacement therapy.

Pompe's Disease (Infantile Onset)>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteHematologyInternal MedicineNeurologyPediatrics

Migraine Prevention: Atogepant for Kids

We are studying the long-term safety and tolerability of atogepant in children and teens aged 6 to 17 with migraines. This research aims to ensure the treatment is safe for young patients.

Migraine1-2 yearsConfirmation phase (III)11-15 visitsNo PlaceboStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Episodic Migraine: Atogepant for Kids and Teens

We are studying the safety and effectiveness of Atogepant tablets for children and teens aged 6 to 17 with episodic migraines. This trial compares the medication to a placebo to see if it helps reduce migraine symptoms.

Episodic Migraine3-6 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteNeurologyPediatrics

Children's Experience After General Anesthesia: Sedation Study

We are examining how different sedative medications impact children's recovery after surgery. The goal is to see if these medications can help reduce anxiety and improve overall comfort.

General Anesthesia and Sedation6-12 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesInternal MedicineOtolaryngologyPediatrics

Primary Membranous Nephropathy: Zanubrutinib vs. Tacrolimus

We are studying whether zanubrutinib can reduce protein levels in urine and lead to remission in patients with primary membranous nephropathy compared to tacrolimus. This trial aims to evaluate the safety and effectiveness of both treatments.

Primary Membranous Nephropathy1-2 yearsEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteNephrology

Stroke Prevention: Milvexian Study

We are testing a new oral medication, milvexian, for individuals who have had an acute ischemic stroke or high-risk transient ischemic attack. The study aims to see if it can lower the risk of future strokes and other heart-related issues.

Acute Ischemic Stroke and High-Risk Transient Ischemic Attack>2 yearsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Diffuse Large B-Cell Lymphoma: Acalabrutinib with R-miniCHOP

We are studying whether adding acalabrutinib to a reduced chemotherapy regimen helps older adults with untreated diffuse large B-cell lymphoma live longer and have better treatment responses. This trial is for those over 60 or 80 years who cannot receive full-dose chemotherapy.

High-Grade B-Cell Lymphoma>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology

Heart Failure in Children: Vericiguat Study

We are studying a new medication, vericiguat, to see if it helps improve heart function in children with heart failure. The trial compares its effects to a placebo to ensure safety and effectiveness.

Chronic Systolic Heart FailureEfficacy phase (II)Confirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyPediatrics

Cancer Treatment: Long-term Study of Pembrolizumab

We are evaluating the long-term safety and survival of patients currently on pembrolizumab treatment. This study aims to understand how well the treatment works and its effects over time.

Advanced Cancer>2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncology

Multiple Sclerosis: Ozanimod vs. Fingolimod

We are studying whether the new medication ozanimod is more effective and safe than fingolimod for children and adolescents with relapsing remitting multiple sclerosis. This trial will also assess how the body handles ozanimod.

Relapsing-Remitting Multiple SclerosisConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesNeurology

Rituximab for Progressive Interstitial Lung Disease

We are studying whether rituximab can improve lung function in patients with progressive interstitial lung disease. This trial compares its effects to a placebo to assess safety and quality of life.

Interstitial Lung Disease>2 yearsEfficacy phase (II)Confirmation phase (III)≤5 visitsStandard MedicinesInternal MedicinePulmonology

Severe Eosinophilic Asthma: Benralizumab for Kids

We are studying whether benralizumab can help children with severe eosinophilic asthma by reducing asthma attacks and improving their symptoms. This trial will also look at the safety of the medication.

Severe Eosinophilic Asthma>2 yearsConfirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesPartially RemoteAllergologyPulmonology

Severe Pneumonia: Testing Trimodulin

We are studying whether trimodulin can improve survival in hospitalized adults with severe pneumonia compared to a placebo. The trial also looks at the safety and effects of the treatment.

Community Acquired PneumoniaConfirmation phase (III)≤5 visitsInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Axial Spondyloarthritis: Filgotinib Study

We are testing the medication filgotinib in adults with active axial spondyloarthritis to see if it improves symptoms and physical function compared to a placebo. The study also looks at the safety of this treatment.

Axial Spondyloarthritis>2 yearsConfirmation phase (III)11-15 visitsStandard MedicinesCost ReimbursementPartially RemoteInternal MedicineRheumatology